We have recently shown that donor CD4-enriched cells of Th2 cytokine phenotype, generated by treating mice in vivo with a combination of interleukin-2 (IL-2) and IL-4, prevent lipopolysaccharide-induced, tumor necrosis factor-cu-mediated lethality during graft-versus-host reaction. To assess the potential regulatory role of such Th2-type cells in lethal graft-versus-host disease (GVHD) and graft rejection, we used a fully allogeneic murine transplant model using sublethally irradiated hosts (B6 --t C3H. 500 cGy). Such recipients generated a strong host-versus-graft response, as reflected by their ability to reject T-cell-depleted inocula. The administration of T-cell-containing donor whole spleen inocula resulted in alloengraftment, but such recipients developed lethal GVHD. However, mice receiving sequential donor LLOGENEIC BONE MARROW transplantation (AlloBMT) as a therapeutic m~d a l i t y "~ is currently limited by both donor and host T-lymphocyte-mediated alloreactions. For example, the graft-versus-host reaction (GVHR) is manifested clinically as graft-versus-host disease (GVHD) and accounts for the majority of the morbidity and mortality associated with AlloBMT.' Additionally, host-versus-graft (HVG)-mediated rejection has recently re-emerged as a significant clinical problem with the increased rate of graft rejection in recipients of T-cell-depleted (TCD)6 marrow. Because T-lymphocyte-mediated alloreactivity is central in the pathogenesis of both GVHD7 and graft rejection,8 an ability to regulate such alloreactions is critical for efforts to expand the applicability of AlloBMT.
LLOGENEIC BONE MARROW transplantation (AlloBMT) as a therapeutic m~d a l i t y "~ is currently limited by both donor and host T-lymphocyte-mediated alloreactions. For example, the graft-versus-host reaction (GVHR)
is manifested clinically as graft-versus-host disease (GVHD) and accounts for the majority of the morbidity and mortality associated with AlloBMT.' Additionally, host-versus-graft (HVG)-mediated rejection has recently re-emerged as a significant clinical problem with the increased rate of graft rejection in recipients of T-cell-depleted (TCD)6 marrow. Because T-lymphocyte-mediated alloreactivity is central in the pathogenesis of both GVHD7 and graft rejection,8 an ability to regulate such alloreactions is critical for efforts to expand the applicability of AlloBMT.
The observation that TCD of marrow allografts effectively prevents GVHD, but at the expense of an increase in graft rejection, suggests that the T cells mediating GVHR and HVGR are reciprocally related'; indeed, residual host T cells surviving intensive preparative regimens" can mediate graft rejection in the setting of TCD-AlloBMT. In addition to an increased rate of graft rejection, recipients of TCD marrow allografts have an increase in tumor recurrence and infectious complications. 6 Therefore, it appears that an ability to administer functional donor T-cell populations might be advantageous in the AlloBMT setting. As a result, investigators have devised various strategies for the transfer of donor T cells capable of abrogating HVG (or for mediating a graftversus-leukemia effect [GVL] ) without resultant GVHD. For example, the selective depletion of CD8+ lymphocytes from allografts," the delayed transfer of donor T lymphocytes," and the quantitative addback of graded numbers of T cells to TCD-allografts" represent attempts to enhance immunity after BMT without causing GVHD. As an alternative to these strategies, we have investigated whether donor CD4' cells of different functional subsets might regulate GVH and HVG alloreactions.
Murine,14 and now human," CD4' T-cell clonal subsets can be defined by dichotomous cytokine production; the "Thl" subset produces interleukin-2 (IL-2) and interferony (IFN-y), whereas the "Th2" subset produces IL-4 and IL-10. As shown in multiple murine and human infectious disease states,I6 the significance of Thl-or Th2-type polarization of CD4' cytokine production is evidenced by Thll Th2 influences on the nature of the systemic immune response in vivo. For example, Thl-type immune responses are characterized by CD8+ T-cell expansion and the development of cell-mediated immunity (CMI), whereas Th2-type responses appear to inhibit CMI. Because GVHD7 and graft rejectionI7 are both mediated by cellular effectors (in particular, CD8+ T cells), they can be generally classified as "Thltype" immune responses. We therefore hypothesized that cells of Th2 cytokine phenotype might regulate these in vivo alloreactions; indeed, we have recently shown that donor CD4-enriched cells of Th2 cytokine phenotype (generated by treating mice in vivo with IL-2 and IL-4) prevent lipopolysaccharide (LPS)-induced, tumor necrosis factor-a (TNF-a)-mediated murine lethal GVHR." In light of this result, we evaluated the potential role of these Th2-type donor cells in the regulation of GVHD (as defined by histologic changes and lethality) and graft rejection.
To simultaneously study both graft rejection and GVHD, we developed a fully allogeneic murine transplantation model using sublethally irradiated hosts (B6 -+ C3H; 500 cGy). Because such recipients can generate a potent rejection response, this model allows the study of the balance between the donor and host T-cell populations that mediate GVHR and HVGR, respectively. In this study, we show that donor CD4-enriched cells of Th2 cytokine phenotype reduce the histopathologic changes and lethality of GVHD. Our obser- * Thl inoculum consisted of 90 x 10' whole spleen cells from B6 mice, administered IV 4 to 6 hours after host irradiation. vation that the sequential administration of naive donor whole spleen cells ("Thl-type") and CD4-enriched cells from IL-2LL-4-treated donors ("Th2-type") abrogates graft rejection with reduced GVHD illustrates the importance of timing in the administration of functionally distinct donor lymphoid populations and suggests that the in vivo interaction of Thl-and ThZtype donor T-cell populations is an important parameter in understanding and regulating transplantation responses.
MATERIALS AND METHODS
Mice. C57BU6 (B6, H-2b) and C3wHeJ (C3H, H-2') mice were bred at the Frederick Cancer Research Center (Frederick, MD). All mice were used at 8 to 20 weeks of age and were maintained in a specific pathogen-free facility at the National Institutes of Health (NIH; Bethesda, MD).
In vivo generation of donor CD4-enriched cells of Th2 cytokine phenorype. Donor-type B6 mice were injected for 5 days (intraperitonealy [IP] twice daily [TID]) with recombinant human IL-2 (rhIL-2; 25,000 Cetus Units; provided by Chiron Corp, Emeryville, CA) and recombinant murine (rmIL-4; 500 ng; Peprotech, Inc [Rocky Hill, NJ]; provided by Dr Scott Duram, National Cancer Institute, Bethesda, MD). CM-enriched spleen cells from cytokine-treated or control mice were obtained by harvesting of spleens into a singlecell suspension, removal of B cells (goat antimouse magnetic bioparticles; Advanced Magnetics, Cambridge, MA), and depletion of CD8' cells by treatment with culture supernatant from clone 83-12-5 (anti-CD8)I9 and guinea pig complement (GIBCO, Grand Island, NY). The TCD population from cytokine-treated mice was generated by complement treatment of the splenic single-cell suspension after incubation with supernatant from clone HO-13-4 (anti-Thy 1.2).20
Allogeneic cell transfers. Recipient C3H mice were sublethally irradiated (500 cGy; 13'Cs y radiation source; Gamma Cell 40; Atomic Energy of Canada, Ltd. Ottawa, Canada) at a dose rate of 115 cGy/min. Four to six hours later, recipients were injected intravenously [IV] with a single-cell suspension of 90 X lo6 unfractionated spleen cells from untreated B6 donor mice; alternatively, some mice received TCD B6 spleen cells (Table 1 , group 2). GVHD control mice received no additional treatment (group 1; "Thl"); other mice received additional donor CDCenriched cells of Th2-type either immediately (day 0; group 4), 24 hours (day 1; groups 5 and 6), or 72 hours (day 3; group 7) after the initial allogeneic transfer; control mice received additional donor CW-enriched cells from untreated mice (group 8).
Pathologic examination of tissues. Cohorts of mice receiving only the allogeneic whole spleen cell inoculum ("Thl-type") or additional donor CW-enriched cells of Th2 cytokine phenotype ("Thl-+ Th2-type") were killed on day 14 posttransplant, and tissues were taken for histopathologic analysis (Table 1 , groups 1 and 6, respectively; such subjects were also evaluated for chimerism, as described below). Liver, small intestine, colon, and skin were placed in 10% neutral buffered formalin and imbedded in paraffin, and 6-pm thick sections were stained with hematoxylin and eosin (H & E). The samples were examined in a blinded fashion by light microscopy, and each organ was graded semiquantitatively as 0 to 4+ (no change to severe GVHD). Grading of hepatic GVHD was grade 0, no lesions; grade l+, minimal periductal lymphoid cell infiltrates; grade 2+, minimal periductal and perivascular lymphoid intraepithelial lymphocytes; grade 3+, most crypts with small to moderate numbers of degenerative epithelial cells, increased numbers of intraepithelial lymphocytes, and presence of crypt abscesses; and grade 4+, most crypts with moderate numbers of degenerative epithelial cells, extensive intraepithelial lymphocytes and crypt abscesses, and evidence of epithelial erosion or ulceration. Skin was rarely positive for any lesions of GVHD, and was thus not included in the analysis.
Chimerism analysis by frow cytornetry (FCM). Mice receiving
only the TCD or CDcenriched, Th2-type inocula ( Table 1 , groups 2 and 3) were killed on day 14 for chimerism analysis. All other treatment groups were observed for lethality, and subjects surviving more than 60 days posttransplant were then killed and evaluated. Splenic single-cell suspensions were prepared, stained, and analyzed by two-color FCM analysis as previously described.*' Reagents used included biotinylated and fluorescein isothiocyanate (FlTC)-labeled anti-CD4 and anti-CD8 (GenTrak, Inc, Plymouth Meeting, PA) and FITC-conjugated a11ti-H-2~ (clone 20-8-6; generously provided by Julie Titus, NIH). Levels of donor chimerism were calculated as the percentage of donor chimerism = (donor cells/[host + donor cells]) X 100%. Graft rejection was defined as greater than 95% hosttype. chimerism; engrafted recipients typically had greater than 90% donor-type chimerism.
Statistical analysis. Mice were examined daily for morbidity and mortality and were humanely killed if preterminal symptoms of GVHD developed. Survival data were plotted (see Fig 2) and analyzed by the nonparametric rank sum analysis of Wilcoxin ( P values of <.05 were considered significant; long-term survivors were included in the analysis). Mean time to lethality was calculated by analysis of the time of death in those recipients undergoing lethality in the first 30 days posttransplant (long-term survivors were excluded from this analysis). Recipients that rejected the allograft were not included in the lethality analyses.
RESULTS
The administration of B6 donor whole spleen cells (' 'Thltype") is necessary for the alloengraftment of sublethally irradiated C3H recipients. Sublethally irradiated C3H recipients (500 cGy) had preservation of an HVG rejection response, as shown by their ability to reject TCD B6 allogeneic inocula (Table 1 , group 2; 016 mice engrafted at day 14 posttransplant). We first determined whether B6 donor naive whole spleen cells would modulate graft rejection in this model. Given that alloreactive lymphocytes produce Thl-type cytokines22 and typically result in a cell-mediated immune response in vivo (involving both CD4' and CD8+ T lymphocyte^),^^ allotransfers containing unfractionated, naive splenic T cells are here referred to as "Thl-type" inocula. As shown in Fig lA, recipients of B6 whole spleen inocula (90 X lo6 cells; "Thl") were alloengrafted (>90% donor-type lymphoid chimerism). This result was consistently observed, as only 7 of 46 (15.2%) of such recipients rejected the allograft (Table 1, group l) ; the administration of lower doses of B6 whole spleen cells resulted in a higher rate of graft rejection (data not shown). As a result of these observations, all experiments used an allogeneic inoculum of 90 X lo6 unfractionated whole spleen cells to consistently overcome graft rejection and establish alloengraftment in the sublethally irradiated C3H recipients.
We have recently shown" that the in vivo treatment of donor B6 mice for 5 days with a combination of IL-2 and IL-4 generates a CD4-enriched population of Th2 cytokine phenotype, as defined by increased production of L -4 and IL-10 and decreased production of IL-2 and IFN-7. In an LPS-induced model of lethal GVHR, this Th2-type donor population protected mice from otherwise lethal allogeneic inocula. To evaluate whether such Th2-type cells might also regulate the HVG rejection reaction, sublethally irradiated C3H mice received donor CD4-enriched cells from IL-2LL-4-treated B6 donor mice. As shown in Fig 1B ("Th2") , such recipients lacked any appreciable level of allochime- Table 1 , group 6; n = 2 9 ; curve A v C P .OOOll or on day 3 (curve B; "Thl -+ Th2, day 3"; Table 1 , group 7; n = 18; curve B v C P = .OOO2). Recipients were observed for lethality; survival results were pooled from five independent experiments. P values were determined by the nonparametric rank sum analysis of Wilcoxin.
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rism; this result was consistently observed (Table l , group 3; 0/9 mice engrafted at day 14 posttransplant).
Because the donor cells of Th2-type were unable themselves to abrogate HVG and engraft sublethally irradiated hosts, we next evaluated whether engraftment could be established by the sequential administration of donor whole spleen cells (day 0) and CD4-eKiched, Th2-type cells (days 1 or 3). The representative example shown in Fig 1C ( "Thl + Th2"; day-l4 splenic chimerism evaluation) illustrates that alloengraftment was observed in such recipients. This result was consistently observed (Table 1 , groups 6 and 7; graft rejection observed in 4/51 [7. 8%] of such Thl + Th2 recipients). The additional administration of donor CDCenriched cells of Th2-type thus did not inhibit alloengraftment, and such Thl--+ Th2-type donor cell transfers were then evaluated in subsequent GVHD experiments.
Donor whole spleen inocula su.cient to overcome rejection generate lethal GVHD. As discussed above, alloengraftment was consistently observed in sublethally irradiated C3H recipients of 90 X lo6 naive unfractionated whole spleen cells. However, successful engraftment of this T-cellcontaining donor inoculum resulted in acute lethality in the vast majority of recipients (Table 1, Days Post-Allotransfer the additional administration of donor CDCenriched cells of Th2 cytokine phenotype might regulate GVHD. The administration of donor Th2-type cells, in fact, did improve survival for recipients of the day 0 whole spleen allogeneic inoculum. Protection from lethality was greatest when the Th2-type inocula was administered 24 hours after the whole spleen inocula (Fig 2, " Thl" v "Thl + Th2, day 1"; P <
.OOOl); recipients of the day 1 Th2-type inocula were also more likely to become long-term survivors ( To assess whether timing of the Th2-type donor inoculum influenced survival, some C3H recipients received the additional Th2-type cells on day 3. Although lethal GVHD was attenuated in recipients of the day 3 Th2-type inocula (Fig  2; "Thl" v "Thl -+ Th2, day 3"; P = .0002), long-term survival was not statistically different from that of GVHD controls ( Table 1 , 2/39 ["Thl"] v 4/18 ["Thl + Th2, day l " ] mice survived >30 days posttransplant; P = ,125). Additionally, the time to lethality in recipients of the day 3 Th2 inocula was minimally, but not significantly, delayed (median time to lethality of 16.9 v 14.5 days for mice receiving only the whole spleen inocula; P = ,100). Thus, the Th2- Tissues were processed, evaluated in a blinded fashion, and scored on a 0 through 4 scale (no change to severe GVHD).
t Donor CD4' and CD8' lymphoid splenic engraftment was determined by FCM analysis, and calculated using the formula: Donor CD4 + * "Thl" mice ( Table 1 , group 1) received whole spleen cells from E6 mice (day 0; 90 x lo6, injected IV).
5 "Thl --t Th2" mice ( type cell regulation of lethal GVHD was most effective when administered shortly (day 1) after the whole spleen inocula. Interestingly, the coadministration (day 0) of both naive whole spleen and Th2-type cells conferred no protection from lethal GVHD ( Table 1 , group 4; lethality in 11/11 recipients).
To determine whether the CD4+ T-cell population from cytokine-treated mice was necessary for the observed protection from lethal GVHD, the CDCenriched spleen cell population from IL-2nL-4-treated donor mice was depleted of CD4+ cells. Recipients of such inocula ( Table 1, group 9) were not protected from acute lethality (0/8 survivors), thus establishing that the CD4+ cells from L-2LL-4-treated mice were necessary for protection from GVHD. Furthermore, to evaluate whether the cytokine phenotype of donor CD4+ cells was related to the observed reduction in GVHD, a separate control group received the additional administration of naive donor CD4-enriched cells. Such recipients were not protected from lethality (Table 1 , group 8; 0/8 survivors), thereby indicating that the Th2 cytokine phenotype of additional donor CD4+ cells was necessary for demonstrating protection from lethality. Donor CD4-enriched cells of Th2 cytokine phenotype protect recipients from the histopathologic liver and intestinal lesions of GVHD. After establishing that the delayed administration of additional donor CDCenriched cells of Th2 cytokine phenotype prolonged survival, we asked whether this protection was associated with a reduction in GVHD as defined by histologic criteria. Cohorts of mice were killed on day 14 posttransplant, and tissues were processed and semiquantitatively scored in a blinded fashion for lesions of GVHD. Moderate to severe GVHD-induced liver and intestinal changes were observed in 3 of 4 recipients of the whole spleen cell inocula (Table 2 ; "Thl"). Figure 3A illustrates the liver lesions found in these mice; the extensive periportal infiltration of lymphocytes and lymphoblasts, with associated multifocal, single-cell hepatocellular necrosis are consistent with severe hepatic GVHD.x In contrast, Fig 3B shows that recipients of additional donor cells of Th2-type ( Table 2 , "Thl -+ Th2") had a reduction in hepatic GVHD lesions; the liver is relatively normal in appearance, with only minimal periportal mononuclear cell infiltration and no evidence of hepatocellular necrosis. As shown in Table 2 , the protection from hepatic GVHD conferred by the donor Th2-type cells was consistently observed; in fact, 2 of 4 mice in this cohort had completely normal appearing livers, without histologic evidence for GVHD (multiple sections from 2 separate liver lobes were evaluated).
In addition to protection from hepatic GVHD, Thl + Th2 recipients were relatively spared of small intestinal and colonic lesions of GVHD. Figure 4 shows photomicrographs of H & E-stained intestinal tissue sections from representative Thl and Thl -+ Th2 recipients. Figure 4A (Thl recipient) illustrates the increased numbers of intraepithelial lymphocytes and clusters of necrotic crypt epithelial cells characteristic of severe intestinal GVHD.25 Similar lesions were seen in both the small intestine and colon; these recipients also had multifocal mucosal erosion and foci of ulceration in areas of the Peyer's Patches (illustrated in Fig 4B) . In contrast, the Thl -+ Th2 recipients were relatively protected from both small intestinal and colonic lesions of GVHD; the histologically normal small intestine of one such recipient is illustrated in Fig 4C. This protection from intestinal GVHD was marked, as 3 of 4 mice had no evidence of small intestinal or colonic GVHD. Because the intestine was harvested as an "intestinal roll," the entire length of the intestine was available for analysis, and it is thus unlikely that sampling error could account for the lack of lesions observed in the Thl -+ Th2 recipients. Importantly, these differences in histologic GVHD could not be explained by differential alloengraftment; ie, all mice in the day-l4 histologic analysis had predominant allochimerism by FCM analysis, and the Thl -+ Th2 recipients actually had increased absolute numbers of donor cells engrafted (as shown in Table  2 , splenic engraftment analysis). GVHD-induced thymic damage and depletion of the CD4'CD8' thymocyte subpopulation was reduced in recipients of the ThZ-type donor cell inocula. Thl and T h l + Th2 mice undergoing histologic evaluation were also assessed for GVHD-induced thymic changes. On gross examination, 4 of 4 of the Thl recipients had extreme thymic atrophy with an associated low thymocyte count (average of 0.7 X 10' thymocyteshouse). In contrast, 4 of 4 of the T h l -. Th2 recipients had only modest thymic atrophy and significantly higher thymocyte numbers (average of 14.6 X I Oh thymocyteshnouse). Histologically, significant differences were observed between these two treatment groups; compared with control thymic tissue, Thl recipients had marked depletion of thymic lymphocytes, whereas the Thl + Th2 recipients showed a relative preservation of thymic lymphoid cellularity (data not shown).
Because GVHD is known to alter thymocyte subpopulations,*" most notably causing a diminution in the number and percentage of CD4'CD8' thymocyte precursors, we performed FCM on thymocytes from day 14 Thl and T h l + Th2 recipients. Figure SA shows data from a representative Thl recipient and illustrates that these mice displayed the characteristic decrease in the CD4'CD8' thymocyte population seen with GVHD. In contrast, 4 of 4 of the Thl + Th2 recipients had preservation of this CD4'CD8' thymocyte precursor subpopulation (Fig 5B) . Because allotyping of the thymocyte populations was unsuccessful due to low levels of class I surface expression, it is unknown whether the double-positive precursor subpopulation seen in Thl + Th2 recipients was of donor or host origin.
Analysis of long-term survivors (>60 duys posttransplant).
To assess the engraftment and clinical status of survivors of the Thl + Th2 donor cell regimen, subjects surviving more than 60 days were killed for analysis. Such long-term survivors typically showed persistence of allogeneic lymphoid chimerism (average of 92.3% donor-type splenic lymphoid chimerism, n = 8); however, two mice had predominant host-type chimerism (donor type chimerism of 2% and 16.2%). Multilineage engraftment was likely, because spleen cells in the nonlymphoid gate were also of donor type (data not shown; direct staining for nonlymphoid markers was not performed). The immune status of such long-term survivors was markedly abnormal, as evidenced by very low thymocyte (<2 X 10"cells per thymus) and splenocyte numbers ( < I O X IO6 cells per spleen). Additionally, such long-term survivors had marked reductions in the percentage and absolute numbers of splenic CD4' lymphocytes and low proliferative and cytokine responses (data not shown).
DISCUSSION
We have recently shown" that donor cells of Th2 cytokine phenotype regulate ThI-driven, LPS-induced lethal GVHR (unirradiated parent-into-F1 model); the protection conferred by the Th2-type cells was characterized by regulation of both cytokine (IFN-7 and TNF-CY) and cellul& (CD8' alloengraftment) events associated with lethal GVHR. In this study, we extend our previous observations and conclude that donor cells of Th2 cytokine phenotype regulate GVHD in fully allogeneic, irradiated recipients. Th2-type cell regulation of GVHD was observed by prolonged survival and, importantly, through a reduction in the histopathologic tissue damage characteristic of GVHD. Additionally, our observation that sublethally irradiated recipients of fully major histocompatibility complex (MHC)-mismatched donor whole spleen and Th2-type cells engrafted with reduced GVHD shows that T h l m 2 interactions in vivo are important considerations for the administration of functional donor T-cell populations in transplant settings in which bidirectional alloreactivity exists (graft rejection and GVHD). As a result, we propose that a strategy incorporating a "Thl-+ Th2-type" donor cell administration might represent a novel strategy for the abrogation of graft rejection with regulation of GVHD.
The T cells mediating graft rejection and GVHD, the primary barriers for the broadened clinical application of AlIoBMT, appear to exist in a competitive, dynamic balance.
For (Table 2 , "Thl") and illustrates the mononuclear cell infiltration and crypt epithelial cell necrosis (see arrowhead) seen in mice undergoing lethal GVHD. Additionally, as shown in the representative example in (B), these recipients had multifocal mucosal ulceration superficial t o Peyer's Patches (marked by P). In contrast, (C) illustrates that recipients of additional B6 donor CDCenriched cells of Th2-type (Table 2 , "Thl + Th2") had preservation of crypt architecture without evidence for mucosal lesions. Small and large intestinal sections were semiquantitatively scored for GVHD and the results are shown in Table 2 CD8+ cells generate class I-restricted antihost cytotoxic response~,~' whereas others have shown that "veto inactivation" of host cells by donor cells expressing cytotoxic granules can occur'* (data from our laboratory show that the donor Th2-type cells used in this study do not generate significant in vitro cytotoxic responses in allogeneic MLWCML reactions or possess veto cell function; K. Kurasawa, unpublished observations).
In this study, because of the relatively low host irradiation administered, a strong HVG rejection response against allogeneic inocula was generated. Donor T-cell-containing inocula resulting in engraftment in less than 100% of recipients consistently resulted in lethal GVHD ( . This model thus illustrates a critical problem in AlloBMT, ie, the "therapeutic index" for allogeneic T-cell containing inocula (ie, a T-cell dose that will consistently abrogate HVG without GVHD) may in some settings be marginal.
Given this limitation, our observation that the delayed administration of donor CD4-enriched cells of Th2 cytokine phenotype improved survival in recipients of allogeneic inocula has important implications. The sequential Thl-+ Th2-type donor treatment was most protective when the Th2-type cells were administered shortly (day 1) after the initial whole spleen inoculum and when doses of greater than 50 X lo6 Th2-type cells were administered. Our finding that delaying the administration of Th2-type cells to day 3 resulted in a reduction in the protection from GVHD suggests that Thl/Th2 interactions in the transplant setting are of primary importance during the generation of alloresponses. Interestingly, coadministration of the Th2-type cells with the whole spleen inoculum (day 0) did not protect recipients from lethal GVHD ( Table 1 , group 4); this observation illustrates the complex nature of interacting T-cell populations in vivo and further stresses the importance of timing in the interaction of functionally distinct donor T-cell populations. We thus conclude that the parameters of timing and dose are important considerations for strategies attempting to regulate ongoing Thl-type alloresponses with cells of Th2 cytokine phenotype.
The model presented here generates a very aggressive lethal GVHD (median survival time of 14.5 days) with strong histopathologic features of GVHD, and thus represents a stringent model to evaluate methods to regulate allogeneic responses in vivo. As a result, the observed protection from hepatic, small intestinal, and colonic infiltration and necrosis conferred by donor Th2-type cells was revealing (Table 1 and Figs 3B and 4C ). GVHD-induced multiorgan tissue damage contributes greatly to the morbidity and mortality associated with AlloBMT. Intestinal lesions are especially important in severe GVHD33; some investigators have reasoned34 that bacterially derived LPS endotoxin, introduced systemically via GVHD-induced intestinal lesions, results in cytokine-mediated tissue damage (in particular, TNF-a-mediated pathology) and subsequent mortality from GVHD. The absence of intestinal pathology in Thl + Th2 recipients thus may have been an important determinant in the observed survival advantage for this cohort. Interestingly, a recent report35 in a murine parasite model provides additional evidence that cells of Th2 cytokine phenotype regulate intestinal lesions caused by pathogenic Thl-type responses.
The regulation of GVHD conferred by the Th2-type inoculum did not appear to negatively effect the extent or stability of alloengraftment. In fact, as illustrated in the day-l4 splenic analysis shown in Table 2 , the reduced hepatic and intestinal lesions observed in recipients of the Th2-type inoculum occurred concomitant with an increase in the absolute number of donor lymphoid cells engrafted. Additionally, the majority of long-term surviving recipients of the Th2-type inoculum showed persistence of donor-type lymphoid engraftment. These findings thus suggest that the allogeneic reactions accounting for the abrogation of graft rejection and the mediation of GVHD may be distinct. Given that the mechanism of GVHD involves a cytokine cascade," whereas the abrogation of rejection is largely mediated by cytolytic" or veto3' mechanisms, the administration of donor Th2-type cells may therefore regulate cytokine events without compromising the cellular components of the allograft that promote engraftment.
Given that the thymus is an important and very sensitive target tissue of GVHD,37 the partial preservation of thymic histology, numbers, and subpopulations observed in recipiFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From ents of the Thl-+ Th2-type donor inoculum provides further evidence that the Th2-type cells regulated GVHD. In light of a recent studyz6 that illustrates the deleterious effects of GVHR-induced thymic damage on positive and negative selection, this observation has potential relevance for attempts to preserve immunity posttransplant. Although day-l4 thymic parameters in the Thl + Th2 recipients were preserved relative to GVHD control mice, long-term survivors (>60 days posttransplant) of this Thl + Th2 donor inoculum showed evidence for severe thymic-related immunosuppression. Because immunosuppression is probably the most sensitive indicator of GVHD,38 the observed thymic dysfunction and generalized immunosuppression in long-term survivors suggests that, although the Th2-type cells prolonged survival and reduced the histologic changes of GVHD, such survivors most likely had sublethal or chronic GVHD. The regulation of GVHD by donor Th2-type cells was therefore incomplete; we are currently evaluating whether multiple doses or alternative sources of Th2-type cells, or the systemic administration of Th2-type cytokines, might enhance the Th2-effect and result in more complete regulation of GVHD.
The mechanism whereby the Th2-type cells regulate GVHD is currently under investigation and is not completely understood at this time. However, we have previously shown that donor Th2-type cells regulate both cytokine (IFN-y and TNF-a) and cellular (CD8+ alloengraftment) processes associated with GVHR. 18 Recently, we have shown that the Th2-type cells used in these experiments reduce the generation of CD8' cells and cytolytic activity in an in vitro allogeneic MLWCML culture sytem (K. Kurasawa, unpublished observations). Because donor CD8+ cells are' a key effector cell of GVHD, Th2-type cell regulation of CD8' proliferation andor function is one potential mechanism for the protection observed in this model. The diminished cellular infiltration of host tissues observed on histopathologic evaluation of Thl + Th2 recipients further suggests that the Th2-type cells may regulate GVHD by altering cellular processes in vivo. Additionally, because of evidence that the elaboration of cytokines (in particular, T N F d 9 ) is an important contributor to the tissue damage observed in GVHD, regulation of cytokines in vivo may have contributed to the preserved tissue histology observed in recipients of the Th2-type inocula. Given our previous observation that Th2-type donor cells reduce LPS endotoxin-induced TNF-a production in vivo during GVHR, regulation of TNF-a andor other macrophage-derived inflammatory cytokines may have contributed to the protection from GVHD. This possibility is currently under investigation.
This report, by showing that the delayed administration of donor CD4-enriched cells of Th2 cytokine phenotype prolongs survival and reduces histopathogic GVHD-induced tissue lesions, introduces a novel strategy for the regulation of alloreactivity in vivo. Our results illustrate the importance of timing in the administration of functionally distinct donor lymphoid populations and suggest that a strategy incorporating the sequential administration of Thl-and Th2-type donor cells can achieve the abrogation of graft rejection with subsequent regulation of GVHD. Such a "Thl + Th2 strategy" might have application for attempts to decrease graft rejection in the setting of unrelated donor transplants or in transplants using less-intensive preparative regimens. Whether a Th 1 -+ Th2-type donor strategy, by increasing the therapeutic index of allogeneic T-cell transfers, can be used to mediate a graft-versus-leukemia effect is of interest and is under investigation.
